Analytical methods
Single-nucleotide variants and indels are detected by bidirectional sequencing of the 12 exons of SLC39A4 and their flanking intronic sequences, using either Sanger sequencing of PCR products or highthroughput sequencing (HTS) targeting the regions of interest with a recommended minimal read depth of 30 × and preferably of at least 100 × . Whole exome 5 or even whole-genome sequencing may also be used for variant detection, provided the sequence quality meets diagnostic requirements. Larger deletions or duplications involving at least one exon can be found by analysis of HTS data or they can be screened by a quantitative method such as quantitative multiplex PCR of short fluorescent fragments or multiplex ligation-dependent probe amplification.
Analytical validation
The first level of validation is the sequencing of both strands. Any suspected new variant present on both strands is then submitted to an internal validation through analysis of variants found in previous patients; it is also compared with public variant databases (eg, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), Exome Variant Server (http://evs.gs. washington.edu/niehsExome/), 1000 genomes (http://www.1000genomes. org/), ExAC Browser (http://exac.broadinstitute.org/), or LOVD (www. LOVD.nl/SLC39A4)) and its potential deleterious effect on SLC39A4 function is searched through prediction by bioinformatic tools. Singlenucleotide variants or copy-number variations identified through HTS have to be confirmed by Sanger sequencing or by a quantitative method, respectively. Whenever possible, segregation between the variant and the phenotype should be assessed by testing affected/ unaffected relatives and obligatory carriers in the family, to exclude possible variants that would not affect SLC39A4 function.
Estimated frequency of the disease (Incidence at birth (birth prevalence) or population prevalence)
The only data available in literature indicates an incidence of 1:500 000 births in Denmark 6 (http://www.orpha.net/orphacom/ cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf). This is consistent with the frequency of rare variants known to affect or potentially affecting SLC39A4 function, which are released in public variant database, considering an autosomal recessive mode of inheritance. An unofficial study conducted in France in the late 90s identified 15 families. The frequency seems artificially much higher in countries of the Mediterranean basin, probably because of a founder effect due to a higher incidence of consanguinity. 
.3).
Predictive testing-it is not applicable in most cases, because AEZ symptoms and signs occurs in the perinatal period. The value of the genetic test would therefore rather be considered diagnostic than predictive. Prenatal-it is technically feasible, but it is not recommended. Zinc supplementation can indeed be applied immediately in a newborn suspected of AEZ on the basis of a zinc dosage (see 3.1.2). Besides, the risk for the mother inherent to prenatal testing cannot be neglected. Genetic testing comes in a second time, in order to confirm clinical diagnosis. 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Theoretically 100% if variants affecting SLC39A4 function are localized within exons or flanking introns sequences, which encompasses at least 80% of this type of variants.
Analytical specificity (proportion of negative tests if the genotype is not present)
100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if quantification can only be made case by case.
Overall, variants affecting SLC39A4 function are observed in about 48% of the index cases tested:~40% of the patients are homozygotes or compound heterozygotes, whereas 8% are heterozygotes only. 8 In these last ones, we cannot exclude the presence of a second anomaly in unexplored regions of the SLC39A4 gene (intronic, promoting, untranslated or even regulatory regions) or in another gene directly involved in zinc homeostasis. 9 Besides, the participation of epigenetic events such as methylation or miRNA regulation cannot be ruled out either. The same hypotheses are also valuable to explain the failure in variant detection in about 52% of the patients. 9 In addition, the difficulty-or even sometimes the impossibility-to distinguish congenital zinc deficiency AEZ from acquired zinc deficiency largely accounts for these negative tests; except for the age at onset, which can be much later in acquired zinc deficiency, both entities share indeed the same clinical features. A few other negative tests are attributable to the partial clinical overlap between AEZ and biotin deficiency, atopic dermatitis or exceedingly rare genodermatoses (Küry et al. manuscript under preparation).
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
If homozygous or compound heterozygous variants affecting SLC39A4 function are identified in still asymptomatic breastfed children-their zinc deficiency is masked by zinc from maternal milk-the risk to develop AEZ after weaning is 100%.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: When a variant affecting SLC39A4 function is identified in the index case, the negative predictive value is 100%.
Index case in that family had not been tested: Not applicable.
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.10 'A' was marked)
Can a diagnosis be made other than through a genetic test?
No □ (Continue with 3. 3.1.2. Describe the burden of alternative diagnostic methods to the patient Diagnosis can be established by the concomitant presence of characteristic clinical features and biological signs. Historically, AEZ was defined by a triad of symptoms, including a periacral and periorificial dermatitis, an alopecia and a diarrhea. 10 In practical terms, this pathognomonic triad is seen in only 25% of the cases. 11 The most constant clinical symptoms are cutaneous lesions (first eczematous, then quickly erosive, psoriasiform or vesiculopustulous) always located at least in periorificial areas, and very frequently associated with acral lesions. Secondary fungal and bacterial infections, erosions of the buccal mucosa, integument disorders (alopecia and nail dystrophy), diarrhea, neuropsychiatric symptoms (irritability, apathy or psychomotor delay), and failure to thrive are also frequently reported. 11 The characteristic biological sign of AEZ is a decrease in body zinc levels, usually assessed by a dosage of zinc plasma or serum levels; low levels of zinc-dependent enzymes, such as alkaline phosphatase, are also observed. Consequently, a key element in the diagnosis of AEZ is the excellent responsiveness of zinc deficiency symptoms and signs to oral zinc supplementation; all of them should indeed resolve within days/ weeks. It is worth noting, however, that such a responsiveness to zinc therapy is also observed in transient neonatal zinc deficiency (TNZD), in which maternal milk does not provide enough zinc to meet the infant's needs, despite a normal intestinal absorption. 7 Eventually, interruption of zinc therapy may help to distinguish between inherited (AEZ) and acquired zinc deficiency, as, on the one hand, a relapse is always observed in AEZ, whereas, on the other hand, no further supplementation is required after weaning in TNZD.
How is the cost effectiveness of alternative diagnostic methods to be judged?
Establishing a diagnosis of AEZ is not very easy, because of the rarity of the disease, which often leads to a long diagnostic delay. Moreover, clinical and biochemical diagnostic methods are rarely sufficient to establish a definitive diagnosis of AEZ, notably because acquired zinc deficiency causes are varied and not always obvious to determine. 12, 13 More rarely, biotinidase deficiency and atopic dermatitis are sometimes misdiagnosed as AEZ, especially when zinc levels are found subnormal and symptoms seem zinc responsive. Such situations can be considered as exceptions, but they nevertheless illustrate the difficulty to rely upon zinc dosage and clinical features only, all the more that true AEZ patients also happen to exhibit very marginal decreases in plasma zinc levels. As a matter of fact, zinc homeostasis is so tightly regulated that even the slightest biochemical abnormality can stress a more profound zinc deficiency. Methods for zinc dosage and definition of standard values for zinc levels are not harmonized either between laboratories/countries, which can induce misinterpretation of biochemical results. In any case, the ultimate diagnostic proof of AEZ is therefore brought by the identification of a molecular anomaly in SLC39A4.
Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠ Therapy (please describe)
AEZ patients require a lifelong zinc supplementation. Any interruption of the therapy will inevitably induce a relapse. Prognosis (please describe) Once AEZ diagnosis is established, the prognosis is excellent, provided zinc supplementation is correctly followed. On the contrary, if untreated, patients would experience a progressive alteration of all physiological functions expressed by a large cohort of symptoms, including neurological, immunological and gastrointestinal disorders; this would lead to a generalized organic failure and to death.
Management (please describe)
The result of the genetic test will necessarily influence disease management. Relevance and duration of zinc therapy in a child depend indeed directly on the result of his genetic testing. In homozygotes or compound heterozygotes, confirmation of AEZ diagnosis is essential, because an untreated zinc deficiency may be fatal over the medium to long term; these patients should receive a lifelong zinc treatment. On the other hand, patients with no variant identified probably have an acquired zinc deficiency, which may resolve either spontaneously or once the true cause of the disease is determined and treated. In any case, a regular clinical and biological follow-up of the patients enables to adapt the dose of zinc supplement to possible physiological (eg, adolescence, pregnancy) or pathological (eg, inflammatory states) variations of zinc levels.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked) 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Results of SLC39A4 genetic testing may have no immediate medical consequence, because zinc supplementation has almost always been proposed to patients prior to the request for genetic analysis. Yet, in
